Healthcare Industry News: Millennium
News Release - May 1, 2007
ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEOLEXINGTON, Mass., May 1 (HSMN NewsFeed) -- ActivBiotics, Inc. announced today that its board of directors has appointed Steven C. Gilman, Ph.D. as chairman and chief executive officer. Dr. Gilman was previously the company's president and chief executive officer.
Dr. Gilman joined ActivBiotics in March 2004 as president and chief executive from Millennium Pharmaceuticals where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for the inflammation business. Prior to Millennium, he was Group Director of the arthritis, pulmonary, immunology and antibacterial therapeutic areas at Pfizer Global Research and Development. He has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He currently serves on the board of the Massachusetts Biotechnology Council and Nextcea, Inc., an early-stage private company. Dr. Gilman received his PhD and MS degrees in microbiology from Pennsylvania State University and his post-doctoral training at Scripps Clinic and Research Foundation.
Dr. Gilman succeeds Alan W. Dunton, M.D., who resigned as non-executive chairman earlier this year to become the CEO of Panacos Pharmaceuticals.
About ActivBiotics, Inc.
ActivBiotics, Inc. is a private biopharmaceutical company located in Lexington, Massachusetts, that is focused on the development and commercialization of novel therapies for the treatment of inflammatory diseases and bacterial infections. The Company's most advance product candidate, rifalazil, has been studied in over 600 patients and volunteers in Phase I-III clinical trials. The Company recently completed enrollment in a Phase III study of rifalazil for the treatment of patients with intermittent claudication, a common manifestation of peripheral arterial disease. In addition, the company is planning to initiate Phase II studies of M40403, a novel anti-inflammatory agent, for the treatment of post-operative ileus and other inflammatory diseases. The Company also has a library of over 1500 compounds with potent antibacterial activity. For more information on ActivBiotics, please visit our web site at: www.activbiotics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.